Benefits and burdens of newborn screening: Public understanding and decision-making

Personalized Medicine

Volumn 11, Issue 6, 2014, Pages 593-607

  Nicholls, Stuart G ^a   Wilson, Brenda J ^a   Etchegary, Holly ^b   Brehaut, Jamie C ^a,c   Potter, Beth K ^a   Hayeems, Robin ^d,e   Chakraborty, Pranesh ^f   Milburn, Jennifer ^f   Pullman, Daryl ^g   Turner, Lesley ^h   Carroll, June C ⁱ  

^a UNIVERSITY OF OTTAWA   (Canada)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^g MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^h Eastern Health Canada   (Canada)

ⁱ MOUNT SINAI HOSPITAL   (Canada)

Author keywords

anxiety; consent; diagnostic odyssey; knowledge; morbidity; mortality; overdiagnosis; treatment; uncertainty

Indexed keywords

CONFIDENTIALITY; FALSE POSITIVE RESULT; FAMILY DECISION MAKING; HISTORY; HUMAN; INFORMATION SYSTEM; KNOWLEDGE; MORBIDITY; MORTALITY; NEWBORN SCREENING; PARENTAL ATTITUDE; PARENTAL CONSENT; REVIEW;

EID: 84907932390     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.14.46     Document Type: Review

References (152)

1. Burton H, Moorthie S. Expanded newborn screening. A Review of the Evidence. PHG Foundation, Cambridge, UK (2010
2. Green NS, Dolan SM, Murray TH. Newborn screening: complexities in universal genetic testing. Am. J. Public Health 96(11), 1955-1959 (2006
3. Padilla CD, Therrell BL. Newborn screening in the Asia Pacific region. J. Inherit. Metab. Dis. 30, 490-506 (2007
4. Saadallah AA, Rashed MS. Newborn screening: experiences in the Middle East and North Africa. J. Inherit. Metab. Dis. 30(4), 482-489 (2007
5. Bodamer OA, Hoffmann GF, Lindner M. Expanded newborn screening in Europe 2007. J. Inherit. Metab. Dis. 30, 439-444 (2007
6. Burgard P, Rupp K, Lindner M et al. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2. From screening laboratory results to treatment, follow-up and quality assurance. J. Inherit. Metab. Dis. 35(4), 613-625 (2012
7. Therrell BL, Adams J. Newborn screening in North America. J. Inherit. Metab. Dis. 30, 447-465 (2007
8. Borrajo GJC. Newborn screening in Latin America at the beginning of the 21st century. J. Inherit. Metab. Dis. 30, 466-481 (2007
9. Botkin JR, Goldenberg AJ, Rothwell E, Anderson RA, Lewis MH. Retention and research use of residual newborn screening bloodspots. Pediatrics 131, 1-8 (2012
10. Koppaka R. Ten Great Public Health Achievements - United States, 2001-2010. MMWR Morb. Mortal. Wkly. Rep. 60(19), 619-623 (2011
11. Raffle AE, Gray JaM. Screening: evidence and practice. Oxford University Press, Oxford, UK (2007
12. Centerwall SA, Centerwall WR. The discovery of Phenylketonuria: The story of a young couple, two retarded children, and a scientist. Pediatrics 105(1), 89-103 (2000
13. Pollitt RJ. Introducing new screens: why are we all doing different things? J. Inherit. Metab. Dis. 30, 423-429 (2007
14. Arn PH. Newborn screening: current status. Health Aff. 26(2), 559-566 (2007
15. Kaye CI, Accurso F, La Franchi S et al. Newborn screening fact sheets. Pediatrics 118(3), e934-e963 (2006
16. Fowler DJ, Picker J, Waisbren SE, Levy HL. Neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency. Lancet 359(9306), 628 (2002
17. Watson MS, Lloyd-Puryear MA, Mann MY, Rinaldo P, Howell RR. Newborn screening: toward a uniform screening panel and system. Main report. Genet. Med. 8, 12S-252S (2006
18. Botkin JR, Clayton EW, Fost NC et al. Newborn screening technology: proceed with caution. Pediatrics 117(5), 1793-1799 (2006
19. Borte S, Von Dobeln U, Hammarstrom L. Guidelines for newborn screening of primary immunodeficiency diseases. Curr. Opin. Hematol. 20(1), 48-54 (2013
20. Scott CR, Elliott S, Buroker N et al. Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. J. Pediatr. 163(2), 498-503 (2013
21. Discretionary Advisory Committee on Heritable Disorders in Newborns and Children. Nominated Conditions. US Department of Health and Human Services. www.hrsa.gov/advisorycommittees/mchbadvisory/ heritabledisorders/nominatecondition/workgroup.html
22. Wion E, Brantley M, Stevens J et al. Population-wide infant screening for HLA-based type 1 diabetes risk via dried blood spots from the public health infrastructure. Ann. NY Acad. Sci. 1005, 400-403 (2003
23. Hagopian WA, Erlich H, Lernmark A et al. The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants. Pediatr. Diabetes 12(8), 733-743 (2011
24. Kerruish NJ. Parents' experiences of newborn screening for genetic susceptibility to type 1 diabetes. J. Med. Ethics 37(6), 348-353 (2011
25. Kerruish NJ, Campbell-Stokes PL, Gray A, Merriman TR, Robertson SP, Taylor BJ. Maternal psychological reaction to newborn genetic screening for type 1 diabetes. Pediatrics 120(2), e324-e335 (2007)
26. Secretary's Advisory Committee on Heritable Disorders in Newborns and Children. Secretary's Advisory Committee on Heritable Disorders in Newborns and Children. 2013 Annual Report. US Department of Health and Human Services, Washington, DC, USA (2013
27. Green A, Pollitt RJ. Population newborn screening for inherited metabolic disease: Current UK perspectives. J. Inherit. Metab. Dis. 22, 572-579 (1999
28. Paul DB. Patient advocacy in newborn screening: continuities and discontinuities. Am. J. Med. Genet. C. Semin. Med. Genet. 148C(148C), 8-14 (2008
29. Paul DB. Appendix 5: The history of newborn phenylketonuria screening in the US In: Promoting Safe and Effective Genetic Testing in the United States: Final Report of the Task Force on Genetic Testing., Holtzman NA, Watson MS (Eds). NIH, Bethesda, MD, USA, 137-160 (1997
30. Bailey DB Jr, Armstrong FD, Kemper AR, Skinner D, Warren SF. Supporting family adaptation to presymptomatic and 'untreatable' conditions in an era of expanded newborn screening. J. Pediatr. Psychol. 34(6), 648-661 (2009
31. Calonge N, Green NS, Rinaldo P et al. Committee report: Method for evaluating conditions nominated for populationbased screening of newborns and children. Genet. Med. 12(3), 153-159 (2010
32. Andermann A. Revisting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull. World Health Organ. 86(4), 317-319 (2008
33. Petros M. Revisiting the Wilson-Jungner criteria: how can supplemental criteria guide public health in the era of genetic screening? Genet. Med. 14(1), 129-134 (2012
34. Bailey DB Jr, Beskow LM, Davis AM, Skinner D. Changing perspectives on the benefits of newborn screening. Ment. Retard. Dev. Disabil. Res. Rev. 12(4), 270-279 (2006
35. Buchbinder M, Timmermans S. Newborn screening and maternal diagnosis: rethinking family benefit. Soc. Sci. Med. 73(7), 1014-1018 (2011
36. Metcalfe SA, Archibald AD, Atkinson A et al. Conflicting views on newborn and infant genetic screening: perspectives of relatives of children with genetic conditions causing developmental delay and parents of healthy children. Abstracts of the American Society of Human Genetics annual conference. San Francisco, CA, USA, 6-8 November 2012
37. Botkin JR. Assessing the new criteria for newborn screening. Health Matrix 19(16), 163-186 (2009
38. Grosse SD, Boyle CA, Kenneson A, Khoury MJ, Wilfond BS. From public health emergency to public health service: the implications of evolving criteria for newborn screening panels. Pediatrics 117(3), 923-929 (2006
39. Almond B. Genetic profiling of newborns: ethical and social issues. Nat. Rev. Genet. 7, 67-71 (2005
40. Potter BK, Avard D, Entwistle V et al. Ethical, legal, and social issues in health technology assessment for prenatal/ preconceptional and newborn screening: a workshop report. Public Health Genomics 12(1), 4-10 (2009
41. Castellani C, Southern KW, Brownlee K et al. European best practice guidelines for cystic fibrosis neonatal screening. J. Cyst. Fibros. 8(3), 153-173 (2009
42. Godard B, Ten Kate L, Evers-Kiebooms G, Ayme S. Population genetic screening programmes: principles, techniques, practices, and policies. Eur. J. Hum. Genet. 11(Suppl. 2), S49-S87 (2003
43. Bombard Y, Miller FA. Reply to Ross' commentary: Reproductive benefit through newborn screening: preferences, policy and ethics. Eur. J. Hum. Genet. 20, 486-489 (2012
44. Bombard Y, Miller FA, Hayeems RZ et al. Health-care providers' views on pursuing reproductive benefit through newborn screening: the case of sickle cell disorders. Eur. J. Hum. Genet. 20(5), 498-504 (2012
45. Bradley DM, Parsons EP, Clarke AJ. Experience with screening newborns for Duchenne muscular dystrophy in Wales. Br. Med. J. 306(6874), 357-360 (1993
46. Ross LF. Newborn screening for sickle cell disease: whose reproductive benefit? Eur. J. Hum. Genet. 20(5), 484-485 (2012
47. Laird L, Dezateux C, Anionwu EN. Neonatal screening for sickle cell disorders: what about the carrier infants? Br. Med. J. 313, 407-411 (1996
48. Ross LF. Predictive genetic testing for conditions that present in childhood. Kennedy. Inst. Ethics. J. 12(3), 225-244 (2002
49. Hayeems RZ, Bytautas JP, Miller FA. A systematic review of the effects of disclosing carrier results generated through newborn screening. J. Genet. Couns. 17(6), 538-549 (2008
50. Ross LF. Newborn screening for conditions that do not meet the Wilson and Jungner criteria. The case of duchenne muscular dystrophy. In: Ethics and Newborn Genetic Screening. New Technologies, New Challenges. Baily MA, Murray TH (Eds). The Johns Hopkins University Press, Baltimore, MD, USA (2009
51. Kohane IS, Masys DR, Altman RB. The incidentalome. JAMA 196(2), 212-215 (2006
52. Juth N, Munthe C. The Ethics of Screening in Healthcare and Medicine. Serving Society or Serving the Patient? Springer, Dordrecht, The Netherlands (2012
53. Tarini BA, Goldenberg AJ. Ethical issues with newborn screening in the genomics era. Annu. Rev. Genom. Hum. Genet. 13, 381-393 (2012
54. Ross LF. Mandatory versus voluntary consent for newborn screening? Kennedy. Inst. Ethics. J. 20(4), 299-328 (2010
55. Dees RH, Kwon JM. The Ethics of Krabbe Newborn Screening. Public Health Ethics 6(1), 114-128 (2012
56. Miller FA. The sad story of newborn screening for Krabbe: the need for good governance. Public Health Ethics 6(1), 123-126 (2013
57. Ross LF. Newborn screening for Krabbe disease: what Illinois can learn from New York. Public Health Ethics 6(1), 119-123 (2013
58. Ross LF. Newborn screening for lysosomal storage diseases: an ethical and policy analysis. J. Inherit. Metab. Dis. 35(4), 627-634 (2012
59. The President's Council on Bioethics. The Changing Moral Focus of Newborn Screening: An Ethical Analysis by the President's Council on Bioethics. The President's Council on Bioethics, Washington, DC, USA (2008
60. Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. World Health Organization, Geneva, Switzerland (1968
61. Campbell E, Ross LF. Parental attitudes regarding newborn screening of PKU and DMD. Am. J. Med. Genet. 120A(120A), 209-214 (2003
62. Detmar S, Dijkstra N, Nijsingh N, Rijnders M, Verweij M, Hosli E. Parental opinions about the expansion of the neonatal screening programme. Community Genet. 11, 11-17 (2008
63. Lipstein EA, Nabi E, Perrin JM, Luff D, Browning MF, Kuhlthau KA. Parents' decision-making in newborn screening: opinions, choices, and information needs. Pediatrics 126(4), 696-704 (2010
64. Hasegawa LE, Fergus KA, Ojeda N, Au SM. Parental attitudes toward ethical and social issues surrounding the expansion of newborn screening using new technologies. Public Health Genomics 14(4-5), 298-306 (2010
65. Etchegary H, Dicks E, Green J, Hodgkinson K, Pullman D, Parfrey P. Interest in newborn genetic testing: a survey of prospective parents and the general public. Genet. Test. Mol. Biomarkers 16(5), 353-358 (2012
66. Hayeems RZ, Miller FA, Bombard Y et al. Expectations and values about expanded newborn screening: a public engagement study. Health Expect. doi:10.1111/hex.12047 (2013) (Epub ahead of print
67. Muchamore I, Morphett L, Barlow-Stewart K. Exploring existing and deliberated community perspectives of newborn screening: informing the development of state and national policy standards in newborn screening and the use of dried blood spots. Aust. New Zealand Health Policy 3, 14 (2006
68. Plass AM, Van El CG, Pieters T, Cornel MC. Neonatal screening for treatable and untreatable disorders: prospective parents' opinions. Pediatrics 125(1), e99-e106 (2010
69. Quinlivan JA, Suriadi C. Attitudes of new mothers towards genetics and newborn screening. J. Psychosom. Obstet. Gynaecol. 27(1), 67-72 (2006
70. Weinreich SS, Rigter T, Van El CG et al. Public support for neonatal screening for Pompe disease, a broad-phenotype condition. Orphanet. J. Rare Dis. 7, 15 (2012
71. Etchegary H, Dicks E, Hodgkinson K, Pullman D, Green J, Parfey P. Public attitudes about genetic testing in the newborn period. J. Obstet. Gynecol. Neonatal Nurs. 41(2), 191-200 (2012
72. Nicholls SG, Southern KW. Parental decision-making and acceptance of newborn bloodspot screening: an exploratory study. PLoS ONE 8(11), e79441 (2013
73. Grob R. Is my sick child healthy? Is my healthy child sick?: changing parental experiences of cystic fibrosis in the age of expanded newborn screening. Soc. Sci. Med. 67(7), 1056-1064 (2008
74. Gurian EA, Kinnamon DD, Henry JJ, Waisbren SE. Expanded newborn screening for biochemical disorders: the effect of a false-positive result. Pediatrics 117(6), 1915-1921 (2006
75. Waisbren SE, Albers S, Amato S et al. Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA 290, 2564-2572 (2003
76. Hewlett J, Waisbren SE. A review of the psychosocial effects of false-positive results on parents and current communication practices in newborn screening. J. Inherit. Metab. Dis. 29(5), 677-682 (2006
77. Grob R. Parenting in the genomic age: the 'cursed blessing' of newborn screening. New Genet. Soc. 25(2), 159-170 (2006
78. Buchbinder M, Timmermans S. Newborn screening for metabolic disorders: parental perceptions of the initial communication of results. Clin. Pediatr. 51(8), 739-744 (2012
79. Tarini BA, Christakis DA, Welch HG. State newborn screening in the tandem mass spectrometry era: more tests, more false-positive results. Pediatrics 118(2), 448-456 (2006
80. Thelin T, Mcneil TF, Aspegren-Jansson E, Sveger T. Psychological consequences of neonatal screening for alpha-1 antitrypsin Deficiency (ATD). Parental attitudes toward 'ATD-Check-ups' and parental recommendations regarding future screening. Acta Paediatr. Scand. 74, 841-847 (1985
81. Goldstein E, Hermann R, Renfors TJ et al. From genetic risk awareness to overt Type 1 diabetes: parental stress in a placebo-controlled prevention trial. Diabetes Care 32(12), 2181-2183 (2009
82. Lewis S, Curnow L, Ross M, Massie J. Parental attitudes to the identification of their infants as carriers of cystic fibrosis by newborn screening. J. Paediatr. Child Health 42(9), 533-537 (2006
83. Schmidt JL, Castellanos-Brown K, Childress S et al. The impact of false-positive newborn screening results on families: a qualitative study. Genet. Med. 14(1), 76-80 (2012
84. Tluczek A, Koscik RL, Farrell PM, Rock MJ. Psychosocial risk associated with newborn screening for cystic fibrosis: parents' experience while awaiting the sweat-Test appointment. Pediatrics 115(6), 1692-1703 (2005
85. Nicholls SG, Southern KW. Parental information use in the context of newborn bloodspot screening. An exploratory mixed methods study. J. Community Genet. 3(4), 251-257 (2012
86. Davis TC, Humiston SG, Arnold CL et al. Recommendations for effective newborn screening communication: results of focus groups with parents, providers, and experts. Pediatrics 117(5 Pt 2), S326-S340 (2006
87. Detmar S, Hosli E, Dijkstra N, Nijsingh N, Rijnders M, Verweij M. Information and informed consent for neonatal screening: opinions and preferences of parents. Birth 34(3), 238-244 (2007
88. Campbell ED, Ross LF. Incorporating newborn screening into prenatal care. Am. J. Obstet. Gynecol. 190(4), 876-877 (2004
89. Timmermans S, Buchbinder M. Patients-in-waiting: Living between sickness and health in the genomics era. J. Health Soc. Behav. 51(4), 408-423 (2010
90. Timmermans S, Buchbinder M. Saving Babies? The Consequences of Newborn Genetic Screening. The University of Chicago Press, Chicago, IL, USA (2013
91. Bailey DB Jr, Skinner D, Davis AM, Whitmarsh I, Powell C. Ethical, legal, and social concerns about expanded newborn screening: fragile X syndrome as a prototype for emerging issues. Pediatrics 121(3), e693-e704 (2008
92. Tluczek A, Orland KM, Nick SW, Brown RL. Newborn screening: an appeal for improved parent education. J. Perinat. Neonatal Nurs. 23(4), 326-334 (2009
93. Laing IA, Mcintosh N. Practicalities of consent. Lancet 364(9435), 659 (2004
94. Acharya K, Ackerman PD, Ross LF. Pediatricians' attitudes toward expanding newborn screening. Pediatrics 116(4), e476-e484 (2005
95. Hiraki S, Ormond KE, Kim K, Ross LF. Attitudes of genetic counselors towards expanding newborn screening and offering predictive genetic testing to children. Am. J. Med. Genet. Part A 140(21), 2312-2319 (2006
96. Kemper AR, Wake MA. Duchenne muscular dystrophy: issues in expanding newborn screening. Curr. Opin. Pediatr. 19, 700-704 (2007
97. Wilcken B. Ethical issues in newborn screening and the impact of new technologies. Eur. J. Pediatr. 162, S62-S66 (2003
98. Therrell BL, Johnson A, Williams D. Status of newborn screening programs in the United States. Pediatrics 117(5 Pt 2), S212-S252 (2006
99. Ross LF, Saal HM, David KL, Anderson RR, And the American Academy of Pediatrics, American College of Medical Genetics and Genomics. Technical report: ethical and policy issues in genetic testing and screening of children. Genet. Med. 15(3), 234-245 (2013
100. Committee on Bioethics, Committee on Genetics, The American College of Medical Genetics and Genomics Social EaLIC. Ethical and policy issues in genetic testing and screening of children. Pediatrics 131(3), 620-622 (2013
101. Schweers RL. Newborn screening programs: how do we best protect privacy rights while ensuring optimal newborn health? DePaul L. Rev. 61 (2012
102. Foral FE. Necessity's sharp pinch: parental and states' rights in conflict in an era of newborn genetic screening. J. Health Biomed. L. 11(1), 109-128 (2006
103. Uk Newborn Screening Programme Centre. Guidelines for Newborn Blood Spot Sampling. UK Newborn Screening Programme Centre, London, UK (2008
104. Araia MH, Wilson BJ, Chakraborty P et al. Factors associated with knowledge of and satisfaction with newborn screening education: a survey of mothers. Genet. Med. 14, 963-970 (2012
105. Hanley WB. Newborn screening in Canada - Are we out of step? Paediatr. Child Health 10(4), 203-207 (2005
106. Miller FA, Hayeems RZ, Carroll JC et al. Consent for newborn screening: the attitudes of healthcare providers. Public Health Genomics 13(3), 181-190 (2010
107. Dhondt JL. Implementation of informed consent for a cystic fibrosis newborn screening program in France: low refusal rates for optional testing. J. Pediatr. 147(Suppl. 3), S106-S108 (2005
108. Faden R, Chwalow AJ, Holtzman NA, Horn SD. A survey to evaluate parental consent as public policy for neonatal screening. Am. J. Public Health 72, 1347-1352 (1982
109. Annas GJ. Mandatory PKU screening: The other side of the looking glass. Am. J. Public Health 72, 1401-1403 (1982
110. Nicholls SG, Southern KW. Considering consent: a structural equation modelling analysis of factors influencing decisional quality when accepting newborn screening. J. Inherit. Metab. Dis. 37, 197-205 (2014
111. Clarke A. Newborn screening. In: Genetics, Society and Clinical Practice. Harper PS, Clarke A (Eds). Bios, Oxford, UK (1997
112. Murray A, Clarke A. The ethics of population screening. Curr. Paediatr. 12, 447-452 (2002
113. Nicholls SG, Southern KW. Informed choice for newborn blood spot screening in the United kingdom: a survey of parental perceptions. Pediatrics 130(6), e1527-e1533 (2012
114. Hargreaves K, Stewart R, Oliver S. Informed choice and public health screening for children: the case of blood spot screening. Health Expect. 8, 161-171 (2005
115. Parsons EP, King JT, Israel JA, Bradley DM. Mothers' accounts of screening newborn babies in Wales (UK). Midwifery 23(1), 59-65 (2007
116. Newcomb P, True B, Walsh J, Dyson M, Lockwood S, Douglas B. Maternal attitudes and knowledge about newborn screening. MCN Am. J. Matern. Child Nurs. 38(5), 289-294 (2013
117. Deluca JM, Kearney MH, Norton SA, Arnold GL. Parents' experiences of expanded newborn screening evaluations. Pediatrics 128(1), 53-61 (2011
118. Smith RA, Williams DK, Sibert JR, Harper PS. Attitudes of mothers to neonatal screening for Duchenne muscular dystrophy. Br. Med. J. 300, 1112 (1990
119. Tluczek A, Mischler EH, Farrell PM et al. Parents' knowledge of neonatal screening and response to false-positive cystic fibrosis testing. J. Dev. Behav. Pediatr. 13, 181-186 (1992
120. Suriadi C, Jovanovska M, Quinlivan JA. Factors affecting mothers' knowledge of genetic screening. Aust. NZ J. Obstet. Gynaecol. 44, 30-34 (2004
121. Nicholls SG. Knowledge or understanding? Informed choice in the context of newborn bloodspot screening. Public Health Ethics 3(2), 128-136 (2010
122. Warren NS, Carter TP, Humbert JR, Rowley PT. Newborn screening for hemoglobinopathies in New York state: experience of physicians and parents of affected children. J. Pediatr. 100, 373-377 (1982
123. Uk Newborn Screening Programme Centre. Guidelines for Newborn Blood Spot Sampling. UK National Screening Committee, London, UK (2012
124. Moran J, Quirk K, Duff AJA, Brownlee KG. Newborn screening for CF in a regional paediatric centre: The psychosocial effects of false-positive IRT results on parents. J. Cyst. Fibros. 6, 250-254 (2007
125. Parsons EP, Moore C, Israel J, Hood K, Clarke AJ, Bradley DM. Emphasizing parental choice on newborn screening. Br. J. Midwifery 13, 165-168 (2005
126. Nicholls SG. Proceduralisation, choice and parental reflections on Decisions to accept newborn bloodspot screening. J. Med. Ethics 38, 299-303 (2012
127. Tymstra T. False positive results in screening tests: Experiences of aprents of children screened for congenital hypothyroidism. Fam. Pract. 3(2), 92-96 (1986
128. Muchamore I, Morphett L, Barlow-Stewart K. Community Views and Perspectives of Newborn Screening. The Centre for Genetics Education, Sydney, Australia (2006
129. Couzin-Frankel J. Science gold mine, ethical mindefield. Science 324, 166-168 (2009
130. Douglas C, Van El C, Radstake M, Van Teeffelen S, Cornel MC. The politics of representation in the governance of emergent 'secondary use' biobanks: the case of dried blood spot cards in The Netherlands. Stud. Ethics Law. Technol. 6(1), Article 4 (2012
131. Bombard Y, Miller FA, Hayeems RZ et al. Citizens' values regarding research with stored samples from newborn screening in Canada. Pediatrics 129, 239-247 (2012
132. Lewis MH, Scheurer ME, Green RC, McGuire AL. Research results: Preserving newborn blood samples. Sci. Transl. Med. 4(159), 1-3 (2012
133. Armstrong J. Storage of newborns' blood samples raises privacy concerns Globe and Mail. www.theglobeandmail.com/news/british-columbia/ storage-of-newborns-blood-samples-raises-privacy-concerns/ article4318768
134. Davey A, French D, Dawkins H, O'Leary P. New mothers' awareness of newborn screening, and their attitudes to the retention and use of screening samples for resarch purposes. Genomics Society Policy 1(3), 41-51 (2006
135. Gustafsson Stolt U, Liss P-E, Svensson T, Ludvigsson J. Attitudes to bioethical issues: a case study of a screenig project. Soc. Sci. Med. 54, 1333-1344 (2002
136. Botkin JR, Rothwell E, Anderson R et al. Public attitudes regarding the use of residual newborn screening specimens for research. Pediatrics 129(2), 231-238 (2012
137. Parsons EP, Israel J, Hood K, Bradley DM. Optional screening for DMD: reasons given by mothers for optin in or out. Br. J. Midwifery 14(12), 710-714 (2006
138. Parsons EP. Newborn screening for Duchenne muscular dystrophy: a psychosocial study. Arch. Dis. Child. Fetal Neonatal Ed. 86(2), 91-95 (2002
139. Simpson N, Randall R, Lenton S, Walker S. Audit of neonatal screening programme for phenylketonuria and congenital hypothyroidism. Arch. Dis. Child. Fetal Neonatal Ed. 77, F228-F234 (1997
140. Milburn J, Marcadier J, Rogers I et al. Alerts of potential missed screens in Ontario, Canada. Presented at: 8th ISNS European Meeting. Budapest, Hungary, 4-6 November 2012
141. Hayeems RZ, Miller FA, Little J et al. Informing parents about expanded newborn screening: influences on provider involvement. Pediatrics 124(3), 950-958 (2009
142. Press N, Clayton EW. Genetics and public health: Informed consent beyond the clinical encounter. In: Genetics and Public Health in the 21st Century. Khoury MJ, Burke W, Thomson EJ (Eds). Oxford, NY, USA, 505-526 (2000
143. Kemper AR, Green NS, Calonge N et al. Decision-making process for conditions nominated to the Recommended Uniform Screening Panel: statement of the US Department of Health and Human Services Secretary's Advisory Committee on Heritable Disorders in Newborns and Children. Genet. Med. 16(2), 183-187 (2014
144. Prasad V, Ioannidis JPA. Evidence-based de-implentation for contradicted, unproven, and aspiring healthcare practices. Implement. Sci. 9, 1 (2007
145. Nijsingh N. Krabbe Newborn screening: the issue of informed consent. Public Health Ethics 6(1), 126-128 (2013
146. Goldenberg AJ, Dodson DS, Davis MM, Tarini BA. Parents' interest in whole-genome sequencing of newborns. Genet. Med. 16(1), 78-84 (2013
147. Goldenberg AJ, Sharp RR. The ethical hazards and programmatic challenges of genomic newborn screening. JAMA 307(5), 461-462 (2012
148. Haga SB. Ethical issues of predictive genetic testing for diabetes. J. Diabetes Sci. Technol. 3(4), 781-788 (2009
149. Dewey FE, Grove ME, Pan C et al. Clinical Interpretation and Implications of Whole-Genome Sequencing. JAMA 311(10), 1035 (2014
150. Feero WG. Clinical application of whole-genome sequencing. Proceed with care. JAMA 311(10), 1017-1019 (2014
151. Li C. Personalized medicine - The promised land: are we there yet? Clin. Genet. 79(5), 403-412 (2011
152. Berg JS, Khoury MJ, Evans JP. Deploying whole-genome sequencing in clinical practice and public health: meeting the challenge one bin at a time. Genet. Med. 13(6), 499-504 (2011